Article
Exposure-Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting.
Pharmaceutical research - 1 Oct 2022
Boosman René J, Jebbink Merel, Veldhuis Wouter B, Groenland Stefanie L, van Veggel Bianca A M H, Moeskops Pim, de Langen Adrianus J, Beijnen Jos H, Smit Egbert F, Huitema Alwin D R, Steeghs Neeltje
Abstract excerpt
BACKGROUND: Osimertinib, an irreversible inhibitor of the epidermal growth factor receptor (EGFR) is an important drug in the treatment of EGFR-mutation positive non-small cell lung cancer (NSCLC). Clinical trials with osimertinib could not demonstrate an exposure-efficacy relationship, while a relationship between exposure and toxicity has been found. In this study, we report the exposure-response relationships...
Topics
Join the communities discussing this publication.